Click here to get full coverage on Pfizer ramps up plans for trispecific after ph. 2 eczema win - Fierce Biotech

Pfizer ramps up plans for trispecific after ph. 2 eczema win  Fierce Biotech

Pfizer ramps up plans for trispecific after ph. 2 eczema win - Fierce Biotech

Click here to get full coverage on TSLP links intestinal nutrient sensing with amplification of the ILC2–tuft cell circuit - Nature

TSLP links intestinal nutrient sensing with amplification of the ILC2–tuft cell circuit  Nature

TSLP links intestinal nutrient sensing with amplification of the ILC2–tuft cell circuit - Nature

Click here to get full coverage on TSLP Blockade Emerges as Promising Strategy in Eosinophilic Esophagitis - Physician's Weekly

TSLP Blockade Emerges as Promising Strategy in Eosinophilic Esophagitis  Physician's Weekly

TSLP Blockade Emerges as Promising Strategy in Eosinophilic Esophagitis - Physician's Weekly

Click here to get full coverage on Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis - Business Wire

Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis  Business Wire

Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis - Business Wire

Click here to get full coverage on TSLP still plays well, Generates $400M IPO - bioworld.com

TSLP still plays well, Generates $400M IPO  bioworld.com

TSLP still plays well, Generates $400M IPO - bioworld.com

Click here to get full coverage on Generate:Biomedicines' AI-engineered TSLP antibody headed to Phase III - FirstWord Pharma

Generate:Biomedicines' AI-engineered TSLP antibody headed to Phase III  FirstWord Pharma

Generate:Biomedicines' AI-engineered TSLP antibody headed to Phase III - FirstWord Pharma

Click here to get full coverage on Genistein Reduced Eosinophilic Inflammation and Remodeling by Downregulating PAI-1 and TSLP - Wiley Online Library

Genistein Reduced Eosinophilic Inflammation and Remodeling by Downregulating PAI-1 and TSLP  Wiley Online Library

Genistein Reduced Eosinophilic Inflammation and Remodeling by Downregulating PAI-1 and TSLP - Wiley Online Library

Click here to get full coverage on Endoplasmic reticulum stress enhances the expression of TLR3-induced TSLP by airway epithelium - American Physiological Society Journal

Endoplasmic reticulum stress enhances the expression of TLR3-induced TSLP by airway epithelium  American Physiological Society Journal

Endoplasmic reticulum stress enhances the expression of TLR3-induced TSLP by airway epithelium - American Physiological Society Journal

Click here to get full coverage on Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma - Frontiers

Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma  Frontiers

Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma - Frontiers

Click here to get full coverage on Anti-TSLP Monoclonal Antibody CM326 Shows Efficacy and Safety in CRSwNP - HCPLive

Anti-TSLP Monoclonal Antibody CM326 Shows Efficacy and Safety in CRSwNP  HCPLive

Anti-TSLP Monoclonal Antibody CM326 Shows Efficacy and Safety in CRSwNP - HCPLive

Click here to get full coverage on Type 2 Inflammation Mediates High Airway TSLP in Asthma - European Medical Journal

Type 2 Inflammation Mediates High Airway TSLP in Asthma  European Medical Journal

Type 2 Inflammation Mediates High Airway TSLP in Asthma - European Medical Journal

Click here to get full coverage on Solrikitug Shows Promise as Next-Generation Anti-TSLP Therapy in Asthma, COPD - AJMC

Solrikitug Shows Promise as Next-Generation Anti-TSLP Therapy in Asthma, COPD  AJMC

Solrikitug Shows Promise as Next-Generation Anti-TSLP Therapy in Asthma, COPD - AJMC

Click here to get full coverage on Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI - PR Newswire

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI  PR Newswire

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI - PR Newswire

Click here to get full coverage on Q&A: Long-acting anti-TSLP antibody for severe asthma moves into phase 3 - Healio

Q&A: Long-acting anti-TSLP antibody for severe asthma moves into phase 3  Healio

Q&A: Long-acting anti-TSLP antibody for severe asthma moves into phase 3 - Healio

Click here to get full coverage on An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial - Nature

An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial  Nature

An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial - Nature

Click here to get full coverage on Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario - Fierce Biotech

Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario  Fierce Biotech

Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario - Fierce Biotech

Click here to get full coverage on Windward bags its second China-sourced TSLP-targeting programme - FirstWord Pharma

Windward bags its second China-sourced TSLP-targeting programme  FirstWord Pharma

Windward bags its second China-sourced TSLP-targeting programme - FirstWord Pharma

Click here to get full coverage on Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP - AJMC

Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP  AJMC

Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP - AJMC

Click here to get full coverage on High TSLP and Its Impact on Adult Asthma - European Medical Journal

High TSLP and Its Impact on Adult Asthma  European Medical Journal

High TSLP and Its Impact on Adult Asthma - European Medical Journal

Click here to get full coverage on TSLP promotes GATA3-expressing effector regulatory T cells via DC2 derived from transitional DCs - Nature

TSLP promotes GATA3-expressing effector regulatory T cells via DC2 derived from transitional DCs  Nature

TSLP promotes GATA3-expressing effector regulatory T cells via DC2 derived from transitional DCs - Nature

Click here to get full coverage on TSLP Inhibitors Market Set for Significant Growth During the Forecast Period (2025-2034) Driven by Breakthrough Therapies | DelveInsight - PR Newswire

TSLP Inhibitors Market Set for Significant Growth During the Forecast Period (2025-2034) Driven by Breakthrough Therapies | DelveInsight  PR Newswire

TSLP Inhibitors Market Set for Significant Growth During the Forecast Period (2025-2034) Driven by Breakthrough Therapies | DelveInsight - PR Newswire

Click here to get full coverage on Upstream's TSLP-targeting drug verekitug hits goals in nasal polyp trial - FirstWord Pharma

Upstream's TSLP-targeting drug verekitug hits goals in nasal polyp trial  FirstWord Pharma

Upstream's TSLP-targeting drug verekitug hits goals in nasal polyp trial - FirstWord Pharma

Click here to get full coverage on FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps - Pharmaceutical Executive

FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps  Pharmaceutical Executive

FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps - Pharmaceutical Executive

Click here to get full coverage on HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma - PR Newswire

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma  PR Newswire

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma - PR Newswire

Click here to get full coverage on Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development - GlobeNewswire

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development  GlobeNewswire

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development - GlobeNewswire

Click here to get full coverage on Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD - Patient Care Online

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD  Patient Care Online

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD - Patient Care Online

Click here to get full coverage on Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP and IL-13, Second Asset BEL536, a First-in-class Long-acting Bispecific Targeting OX40L and IL-13, Phase 1 to Start 1Q2026 - Business Wire

Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP and IL-13, Second Asset BEL536, a First-in-class Long-acting Bispecific Targeting OX40L and IL-13, Phase 1 to Start 1Q2026  Business Wire

Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP and IL-13, Second Asset BEL536, a First-in-class Long-acting Bispecific Targeting OX40L and IL-13, Phase 1 to Start 1Q2026 - Business Wire

Click here to get full coverage on Apogee Therapeutics Announces Positive Interim Phase 1 - GlobeNewswire

Apogee Therapeutics Announces Positive Interim Phase 1  GlobeNewswire

Apogee Therapeutics Announces Positive Interim Phase 1 - GlobeNewswire

Click here to get full coverage on FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps - Patient Care Online

FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps  Patient Care Online

FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps - Patient Care Online

Click here to get full coverage on Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept - GlobeNewswire

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept  GlobeNewswire

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept - GlobeNewswire

Click here to get full coverage on Aclaris tests experimental asthma antibody in new human trial - Stock Titan

Aclaris tests experimental asthma antibody in new human trial  Stock Titan

Aclaris tests experimental asthma antibody in new human trial - Stock Titan

Click here to get full coverage on Precision Trading with Kurv Yield Premium Strategy Tesla (tsla) Etf (TSLP) Risk Zones - Stock Traders Daily

Precision Trading with Kurv Yield Premium Strategy Tesla (tsla) Etf (TSLP) Risk Zones  Stock Traders Daily

Precision Trading with Kurv Yield Premium Strategy Tesla (tsla) Etf (TSLP) Risk Zones - Stock Traders Daily

Click here to get full coverage on Verekitug Cuts Polyp Size in Severe CRSwNP, With Joseph Han, MD - HCPLive

Verekitug Cuts Polyp Size in Severe CRSwNP, With Joseph Han, MD  HCPLive

Verekitug Cuts Polyp Size in Severe CRSwNP, With Joseph Han, MD - HCPLive

Click here to get full coverage on Qyuns and Roche partner in $1B+ bispecific antibody deal - bioworld.com

Qyuns and Roche partner in $1B+ bispecific antibody deal  bioworld.com

Qyuns and Roche partner in $1B+ bispecific antibody deal - bioworld.com

Click here to get full coverage on Upstream's Tezspire rival succeeds in Phase II asthma study, but dosing jolts shares - FirstWord Pharma

Upstream's Tezspire rival succeeds in Phase II asthma study, but dosing jolts shares  FirstWord Pharma

Upstream's Tezspire rival succeeds in Phase II asthma study, but dosing jolts shares - FirstWord Pharma

Click here to get full coverage on Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis - The Malaysian Reserve

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis  The Malaysian Reserve

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis - The Malaysian Reserve

Click here to get full coverage on CORRECTED: Chasing pharma heavyweights, Upstream posts phase 2 sinusitis win - Fierce Biotech

CORRECTED: Chasing pharma heavyweights, Upstream posts phase 2 sinusitis win  Fierce Biotech

CORRECTED: Chasing pharma heavyweights, Upstream posts phase 2 sinusitis win - Fierce Biotech

Click here to get full coverage on Study Identifies TSLP as a Major Player in Endometriosis - The American Association of Immunologists

Study Identifies TSLP as a Major Player in Endometriosis  The American Association of Immunologists

Study Identifies TSLP as a Major Player in Endometriosis - The American Association of Immunologists

Click here to get full coverage on As food-allergy disease EoE rises, Israeli team says blocking a protein can shut it down - The Times of Israel

As food-allergy disease EoE rises, Israeli team says blocking a protein can shut it down  The Times of Israel

As food-allergy disease EoE rises, Israeli team says blocking a protein can shut it down - The Times of Israel

Click here to get full coverage on Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - MedCity News

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug  MedCity News

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - MedCity News

Click here to get full coverage on Targeting thymic stromal lymphopoietin in nasal type 2 inflammation - Li - 2025 - Eye & ENT Research - Wiley Online Library

Targeting thymic stromal lymphopoietin in nasal type 2 inflammation - Li - 2025 - Eye & ENT Research  Wiley Online Library

Targeting thymic stromal lymphopoietin in nasal type 2 inflammation - Li - 2025 - Eye & ENT Research - Wiley Online Library

Click here to get full coverage on Monoclonal antibody effects persist for 6 months in patients - Healio

Monoclonal antibody effects persist for 6 months in patients  Healio

Monoclonal antibody effects persist for 6 months in patients - Healio

Click here to get full coverage on Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD - Frontiers

Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD  Frontiers

Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD - Frontiers

Click here to get full coverage on Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - ChartMill

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052  ChartMill

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - ChartMill

Click here to get full coverage on Blocking one protein could prevent food allergy disease - Medical Xpress

Blocking one protein could prevent food allergy disease  Medical Xpress

Blocking one protein could prevent food allergy disease - Medical Xpress

Click here to get full coverage on Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 - National Today

Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026  National Today

Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 - National Today

Click here to get full coverage on Role of thymic stromal lymphopoietin in allergy and beyond - Nature

Role of thymic stromal lymphopoietin in allergy and beyond  Nature

Role of thymic stromal lymphopoietin in allergy and beyond - Nature

Click here to get full coverage on Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress - Yahoo Finance

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress  Yahoo Finance

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress - Yahoo Finance

Click here to get full coverage on Novo Holdings-backed Windward buys rights to Qyuns' clinical-stage immunology bispecific in $700M deal - Fierce Biotech

Novo Holdings-backed Windward buys rights to Qyuns' clinical-stage immunology bispecific in $700M deal  Fierce Biotech

Novo Holdings-backed Windward buys rights to Qyuns' clinical-stage immunology bispecific in $700M deal - Fierce Biotech

Click here to get full coverage on Breakthroughs in asthma therapy - News-Medical

Breakthroughs in asthma therapy  News-Medical

Breakthroughs in asthma therapy - News-Medical

Click here to get full coverage on The anionic surfactant Sodium Dodecyl Benzene Sulfonate alleviates inflammatory responses in atopic dermatitis via NFκB/MAPK pathways in a STAT3-dependent manner - Nature

The anionic surfactant Sodium Dodecyl Benzene Sulfonate alleviates inflammatory responses in atopic dermatitis via NFκB/MAPK pathways in a STAT3-dependent manner  Nature

The anionic surfactant Sodium Dodecyl Benzene Sulfonate alleviates inflammatory responses in atopic dermatitis via NFκB/MAPK pathways in a STAT3-dependent manner - Nature

Click here to get full coverage on Israeli scientists identify protein that could prevent painful food allergy disease - The Jerusalem Post

Israeli scientists identify protein that could prevent painful food allergy disease  The Jerusalem Post

Israeli scientists identify protein that could prevent painful food allergy disease - The Jerusalem Post

Click here to get full coverage on Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma - Nature

Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma  Nature

Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma - Nature

Click here to get full coverage on Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333 - Stock Titan

Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333  Stock Titan

Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333 - Stock Titan

Click here to get full coverage on Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody - Yahoo Finance

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody  Yahoo Finance

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody - Yahoo Finance

Click here to get full coverage on Increased eosinophils after oral corticosteroid treatment for asthma exacerbation correlated with longer ER stays and persisting thymic stromal lymphopoietin and increased Park2 - Nature

Increased eosinophils after oral corticosteroid treatment for asthma exacerbation correlated with longer ER stays and persisting thymic stromal lymphopoietin and increased Park2  Nature

Increased eosinophils after oral corticosteroid treatment for asthma exacerbation correlated with longer ER stays and persisting thymic stromal lymphopoietin and increased Park2 - Nature

Click here to get full coverage on Amgen, AstraZeneca's Tezspire snags rhinosinusitis FDA approval - FirstWord Pharma

Amgen, AstraZeneca's Tezspire snags rhinosinusitis FDA approval  FirstWord Pharma

Amgen, AstraZeneca's Tezspire snags rhinosinusitis FDA approval - FirstWord Pharma

Click here to get full coverage on TSLP acts on regulatory T cells to maintain their identity and limit allergic inflammation - Science | AAAS

TSLP acts on regulatory T cells to maintain their identity and limit allergic inflammation  Science | AAAS

TSLP acts on regulatory T cells to maintain their identity and limit allergic inflammation - Science | AAAS

Click here to get full coverage on Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress - Yahoo Finance

Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress  Yahoo Finance

Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress - Yahoo Finance

Click here to get full coverage on New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care - Stock Titan

New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care  Stock Titan

New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care - Stock Titan

Click here to get full coverage on Aclaris Therapeutics Highlights Upcoming Data Catalysts for AD and Asthma Treatments - National Today

Aclaris Therapeutics Highlights Upcoming Data Catalysts for AD and Asthma Treatments  National Today

Aclaris Therapeutics Highlights Upcoming Data Catalysts for AD and Asthma Treatments - National Today

Click here to get full coverage on Verekitug heads to late-stage trials after Phase II success - Clinical Trials Arena

Verekitug heads to late-stage trials after Phase II success  Clinical Trials Arena

Verekitug heads to late-stage trials after Phase II success - Clinical Trials Arena

Click here to get full coverage on Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378 - PR Newswire

Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378  PR Newswire

Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378 - PR Newswire

Click here to get full coverage on Windward Bio Launches Global Phase 2 Asthma Trial of WIN378 - The Clinical Trial Vanguard

Windward Bio Launches Global Phase 2 Asthma Trial of WIN378  The Clinical Trial Vanguard

Windward Bio Launches Global Phase 2 Asthma Trial of WIN378 - The Clinical Trial Vanguard

Click here to get full coverage on TSLP Inhibitors Emerge as Potential Therapy for Eosinophilic Esophagitis - Research Horizons

TSLP Inhibitors Emerge as Potential Therapy for Eosinophilic Esophagitis  Research Horizons

TSLP Inhibitors Emerge as Potential Therapy for Eosinophilic Esophagitis - Research Horizons

Click here to get full coverage on Tezepelumab alleviates symptoms in severe chronic rhinosinusitis with nasal polyps - 2 Minute Medicine

Tezepelumab alleviates symptoms in severe chronic rhinosinusitis with nasal polyps  2 Minute Medicine

Tezepelumab alleviates symptoms in severe chronic rhinosinusitis with nasal polyps - 2 Minute Medicine

Click here to get full coverage on Epithelial cell-derived cytokine TSLP activates regulatory T cells by enhancing fatty acid uptake - Nature

Epithelial cell-derived cytokine TSLP activates regulatory T cells by enhancing fatty acid uptake  Nature

TSLP

Price Chart

Key Statistics

Top 10 Holdings Distribution

Technicals

About TSLP

Latest News

Pfizer ramps up plans for trispecific after ph. 2 eczema win - Fierce Biotech

TSLP links intestinal nutrient sensing with amplification of the ILC2–tuft cell circuit - Nature

TSLP Blockade Emerges as Promising Strategy in Eosinophilic Esophagitis - Physician's Weekly

Advanced Charts

Fund Information